Abstracts Archive - Page 1918 of 2607 - ACR Meeting Abstracts

Abstract Number: 702 • 2015 ACR/ARHP Annual Meeting
Is Skin Disease More Important to Patients or Physicians in the Assessment of Disease Activity in Psoriatic Arthritis?
Dalton Sholter¹, Proton Rahman², J Antonio Avina-Zubieta³, John Kelsall⁴, Regan Arendse⁵, Majed M. Khraishi⁶, S Shaikh⁷, William G. Bensen⁸, Emmanouil Rampakakis⁹, John S. Sampalis¹⁰, Francois Nantel¹¹, May Shawi¹², Susan Otawa¹³, Cathy Tkaczyk¹³ and Allen J Lehman¹², ¹Rheumatology Associates, Edmonton, AB, Canada, ²Rheumatology, St. Clare's Mercy Hospital, St. John's, NF, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Nexus Clinical Research, St Johns, NF, Canada, ⁷Niagara Peninsula Arthritis Centre, Hamilton, ON, Canada, ⁸St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient (PtGA) and physician (MDGA) global assessment of disease activity are standard outcome measures used in clinical practice and research to ascertain patient and…
Abstract Number: 703 • 2015 ACR/ARHP Annual Meeting
Isotretinoin-Induced Spondilartropathy-Related Symptoms: A Prospective Study
Bunyamin Kisacik¹, Nuriye Kayiran², Orhan Zengin¹, Ali Kalem³, Gezmis Kimyon⁴, Emine Ozkul Kilinc³, Yavuz Pehlivan⁵, Necmettin Kirtak⁶ and Ahmet Mesut Onat⁴, ¹Ä°nternal Medicine Division of Rheumatology, Gaziantep University, Faculty of Medicine, Gaziantep, Turkey, ²physician, Gaziantep, Turkey, ³Physician, Gaziantep, Turkey, ⁴PsART study group, Ankara, Turkey, ⁵Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁶Prof., Gaziantep, Turkey
Background/Purpose: Acne vulgaris is a chronic inflammatory disease of accumulation of the pilosebaceous unit in the skin and has a multifactorial aetiology. Isotretinoin is a…
Abstract Number: 704 • 2015 ACR/ARHP Annual Meeting
Is Axial Involvement Underestimated in Patients with Psoriatic Arthritis? Data from the Bepas Cohort
Kurt de Vlam¹, Rik Lories², Serge Steinfeld³, Filip van Den Bosch⁴, Adrien Nzeusseu Toukap⁵, Michel G. Malaise⁶, Veerle Taelman⁷, Filip van Bruwaene⁸, Marc Vanden Bergh⁹, Rik Joos¹⁰, Jan Lenaerts¹¹, Piet Geusens¹², Silvano Dalli'Armelina¹³, Isabelle Peene¹⁴, Griet De Brabanter¹⁵, Marthe van den Berghe¹⁶, Jiangang Qu¹⁷, Martin Maertens¹⁸ and Hermine Leroi¹⁹, ¹Katholieke Universiteit Leuven, Leuven, Belgium, ²university hospitals leuven, Leuven, Belgium, ³clinique saint jean, bruxelles, Belgium, ⁴Rheumatology, Ghent University Hospital, VIB, Ghent, Belgium, ⁵Department of Rheumatology, Cliniques Universitaires St Luc, Brussels, Belgium, ⁶Department of Rheumatology- GIGA Research - Arthropôle - University of Liège - CHU Liège, Liège, Belgium, ⁷Heilig Hart ziekenhuis, Leuven, Belgium, ⁸H.H. Ziekenhuis, Roeselare, Belgium, ⁹Grand Hôpital de Charleroi Saint Joseph, Charleroi, Belgium, ¹⁰ZNA Jan Palfijn, Antwerpen, Belgium, ¹¹Reuma Instituut, Hasselt, Belgium, ¹²reumaclinic, Genk, Belgium, ¹³Notre Dame de Grace, Gosselies, Belgium, ¹⁴Rheumatology, AZ sint Jan Brugge, 8000 Brugge, Belgium, ¹⁵AZ St Lucas, Assebroek, Belgium, ¹⁶ASZ, Aalst, Belgium, ¹⁷Iris Sud, Bruxelles, Belgium, ¹⁸AZ Damiaan, Oostende, Belgium, ¹⁹MSD Belgium, Bruxelles, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a common form of chronic arthritis strongly associated with the skin disease psoriasis. Although PsA has been included in the…
Abstract Number: 705 • 2015 ACR/ARHP Annual Meeting
Sex Differences in Psoriatic Arthritis: Evaluation of a Real-Life Cohort of 2,118 Italian Patients Treated with Methotrexate
Carlo Selmi^1,2, Elena Generali³, Greta Carrara⁴, Carlo Alberto Scirè⁴ and RECORD Study Group of the Italian Society for Rheumatology, ¹BIOMETRA Department, University of Milan, Milan, Italy, ²Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ³Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁴Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy
Background/Purpose: The influence of sex in psoriatic arthritis (PsA) features and treatment outcomes has not been fully elucidated. We investigated the differences between sexes in…
Abstract Number: 706 • 2015 ACR/ARHP Annual Meeting
Undifferentiated Spondylarthritis May More Frequent in Japanese
Hitoshi Goto¹, Noriyuki Hayashi¹, Shinsuke Yamada² and Masaaki Inaba³, ¹Rheumatology, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatology, Osaka City University Graduate School of Midicine, Osaka, Japan, ³Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Because of low frequency of HLA-B27 (lower than 1%), the prevalence of the spondarthritis (SpA) is thought to be much lower than rheumatoid arthritis…
Abstract Number: 707 • 2015 ACR/ARHP Annual Meeting
Change of Enthesial Involvement Under Treatment Was Independent from the Therapeutic Strategy in Patients with Axial Spondyloarthritis within the Scqm Cohort
Ruediger Mueller¹, Toni Kaegi², Nicole Graf³, Johannes von Kempis⁴ and J.J. Luime⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³graf biostatistics, Winterthur, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…
Abstract Number: 708 • 2015 ACR/ARHP Annual Meeting
Development of an Activity Disease Score in Patients with Uveitis
Esperanza Pato Cour¹, Maria Auxiliadora Martin², Santiago MuÑoz Fernandez³, Adela Castello⁴, Fernando Sanchez-Alonso⁵, David Diaz-Valle⁶, Rosalía Mendez⁷ and Uveitis MeVa Group, ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁴Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain, Madrid, Spain, ⁵Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Clínico San Carlos de Madrid, Madrid, Spain, ⁷Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Uveitis is commonly defined as inflammation of the uvea, the vascular middle layer of the eye. Standardized and validated outcome measures are lacking in…
Abstract Number: 709 • 2015 ACR/ARHP Annual Meeting
Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study
Runsheng Wang¹, Sherine Gabriel² and Michael M. Ward¹, ¹NIH/NIAMS, Bethesda, MD, ²Division of Rheumatology; Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The long-term outcome of patients with non-radiographic axial spondyloarthritis (nr-axSpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective…
Abstract Number: 710 • 2015 ACR/ARHP Annual Meeting
Baseline Characteristics of Early, Delayed, and Non-Responders in a Non-Radiographic Axial Spondyloarthritis Study
Walter Maksymowych¹, Jack F Bukowski², Lisa Marshall³, Annette Szumski⁴ and Heather Jones³, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Clinical Affairs, Pfizer, Collegeville, PA, ³Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁴Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Most clinical trials evaluating anti-TNF agents for treating non-radiographic axial SpA (nr-axSpA) place the primary endpoint at 12 wks, and most formularies require assessment…
Abstract Number: 711 • 2015 ACR/ARHP Annual Meeting
Gender Specific Differences in Ankylosing Spondylitis at Treatment Initiation in Patients Treated with Infliximab or Golimumab
Michael Starr¹, Michel Zummer², Denis Choquette³, Boulos Haraoui⁴, Proton Rahman⁵, Maqbool Sheriff⁶, Niall Jones⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Brendan Osborne¹⁰, Allen J Lehman^10,11, Karina Maslova¹¹, Francois Nantel^12,13 and Cathy Tkaczyk¹⁰, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵Medicine, Memorial University, St John's, NF, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹³19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The prevalence of ankylosing spondylitis (AS) is 2-3 times higher in men compared to women. Recent studies have suggested that clinical differences exist between…
Abstract Number: 712 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort
Mary Gibson¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Colton Pence¹, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: TNF-α inhibitor therapy is recommended by ASAS/EULAR guidelines for ankylosing spondylitis (AS) patients with moderate-to-high disease activity despite inadequate response to NSAIDs in addition…
Abstract Number: 713 • 2015 ACR/ARHP Annual Meeting
Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Juergen Braun⁴, Gustavo Citera⁵, Filip van Den Bosch^6,7, Ronald Pedersen⁸, Randi Bonin⁹, Heather Jones¹⁰, Lisa Marshall¹⁰, Sameer Kotak¹¹, Isabelle Logeart¹², Bonnie Vlahos¹³, Jack F Bukowski⁹ and Walter Maksymowych¹⁴, ¹Rheumatology Department, Hôpital Cochin, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹Clinical Affairs, Pfizer, Collegeville, PA, ¹⁰Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Medical Affairs, Pfizer, France, Paris, France, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: In the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), clinical signs/symptoms and MRI-measured inflammation were evaluated in patients with early, active non-radiographic…
Abstract Number: 714 • 2015 ACR/ARHP Annual Meeting
Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Matthew A. Brown¹, Paul A. Bird², Philip C. Robinson³, Philip J. Mease⁴, Filip van Den Bosch⁵, Christine Surian⁶, Zirke Wiid⁶, Heather Jones⁷, Annette Szumski⁸ and Lisa Marshall⁷, ¹Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ²University of New South Wales, Sydney, Australia, ³University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Australia, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Pfizer Australia, Sydney, Australia, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with tumor necrosis factor α (TNFα) inhibitors has been shown to be effective in improving disease activity and functional capacity in patients with…
Abstract Number: 715 • 2015 ACR/ARHP Annual Meeting
Investigating the Role of Vitamin D in Patients with SLE
Briana K. Ply¹ and Diane L. Kamen², ¹Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Vitamin D is a steroid hormone that not only functions in maintaining calcium and bone metabolism, but also displays immunoregulatory and anti-inflammatory properties. Recent…
Abstract Number: 716 • 2015 ACR/ARHP Annual Meeting
Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
Amita Aggarwal¹, Sudhir sinha², Ranjan Gupta³, Liza Rajasekhar⁴, Akhilesh Yadav³, Ramnath Misra¹ and Virsingh Negi⁵, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ³Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers have a potential for identification, follow-up and assessment of response to treatment in patients with lupus nephritis. Urinary proteomics can help in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].